Fimasartan (BR-A-657) Multiple Oral Dose in Healthy Subjects

BR-A-657 120, 360, or placebo were administered once daily for 7days to 16 healthy male subjects. Pharmacokinetic and Pharmacodynamic(PK/PD) parameters were monitored at pre-specified times from each subjects. PK parameters: Area Under the Curve(AUC), Cmax, half-life, etc. PD parameters: Aldosterone, Plasma renin activity, Angiotensin I, Angiotensin II Adverse events are reported.